Semaglutide Remodels the Gut Microbiome Beyond Its Appetite-Suppressing Action: Sex-Specific Gut-Brain Axis Implications.
7 affiliations
- 1Department of Nutritional Sciences Pennsylvania State University State College Pennsylvania USA.
- 2Department of Physiology and Pharmacology Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary Calgary Alberta Canada.
- 3Institute of Neuroscience and Physiology, University of Gothenburg Gothenburg Sweden.
- 4Wright Labs, LLC Huntingdon Pennsylvania USA.
- 5Department of Biology Juniata College Huntingdon Pennsylvania USA.
- 6Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine University of Calgary Calgary Alberta Canada.
- 7Department of Physiology and Pharmacology Hotchkiss Brain Institute, University of Calgary Calgary Alberta Canada.
Abstract
The gut microbiome communicates bidirectionally with the brain and peripheral metabolic organs to regulate appetite and body weight. Semaglutide (SEMA), a GLP-1 receptor agonist, produces robust weight loss by reducing food intake, largely through brain GLP-1 receptors, yet whether its effects on the gut microbiome are secondary to this centrally driven hypophagia is poorly understood. Given the profound impact of SEMA on food intake and body weight, we propose that SEMA treatment reshapes gut microbial composition and that these shifts are correlated with metabolic outcomes. Diet-induced obese rats received a 4-week SEMA treatment and gut microbial composition was analyzed using 16S rRNA gene sequencing. To differentiate the impact of reduced food intake associated with SEMA from other effects of the drug treatment on the gut microbiome, a pair-fed to SEMA group was tested. SEMA significantly reduced body weight gain and food intake in both sexes. Significant SEMA-induced changes in microbial richness and evenness were detected. Linear discriminant analysis Effect Size (LEfSe) identified enrichment of Firmicutes taxa-particularly members of the Clostridiaceae family-in SEMA-treated rats, whereas controls showed greater representation of Bacteroidota taxa. Sex-specific associations between host metabolic parameters and gut microbial composition were also identified. These findings demonstrate profound, not necessarily health positive, partly sex-specific gut microbial community shifts following GLP-1 analogue treatment. Many of the changes in the gut microbiota were not simply driven by the decreased food intake. Thus, GLP-1 analogue treatment engages the gut microbiome through both food intake-dependent (brain-to-gut) and intake-independent pathways.
Related
- Abdominal Obesity, Brain Glymphatic Function, and LH–dlHPC Appetite Regulation: Current Evidence, Potential Links, and Implications for Metabolic Health
- Exercise and immune system as modulators of intestinal microbiome: implications for the gut-muscle axis hypothesis
- Gut Microbiome in Sporadic Cerebral Small Vessel Disease: MRI-Defined Phenotypes, Mechanistic Evidence, and Nutritional Implications for Brain Aging
- The Gut Microbiome–Estrogen Axis in Menopause: Implications for Body Composition, Cardiometabolic Health and Nutrition
- The Microbiota–Gut–Brain Axis in Obesity: Inflammation, Appetite Dysregulation, and Feeding Behavior
BibTeX
@article{byun2026semaglutide,
title = {{Semaglutide Remodels the Gut Microbiome Beyond Its Appetite-Suppressing Action: Sex-Specific Gut-Brain Axis Implications.}},
author = {Suyeun Byun and Morgan R Sotzen and Madison T Bento and Mya A Knappenberger and Mohammed Asker and Justin R Wright and Regina Lamendella and Chunlong Mu and Karolina P Skibicka},
journal = {Comprehensive physiology},
year = {2026},
month = oct,
doi = {10.1002/cph4.70286},
url = {https://europepmc.org/article/MED/42923050},
note = {CC BY},
}
RIS
TY - JOUR
TI - Semaglutide Remodels the Gut Microbiome Beyond Its Appetite-Suppressing Action: Sex-Specific Gut-Brain Axis Implications.
AU - Suyeun Byun
AU - Morgan R Sotzen
AU - Madison T Bento
AU - Mya A Knappenberger
AU - Mohammed Asker
AU - Justin R Wright
AU - Regina Lamendella
AU - Chunlong Mu
AU - Karolina P Skibicka
PY - 2026
DA - 2026/10/21
JO - Comprehensive physiology
DO - 10.1002/cph4.70286
UR - https://europepmc.org/article/MED/42923050
AB - The gut microbiome communicates bidirectionally with the brain and peripheral metabolic organs to regulate appetite and body weight. Semaglutide (SEMA), a GLP-1 receptor agonist, produces robust weight loss by reducing food intake, largely through brain GLP-1 receptors, yet whether its effects on the gut microbiome are secondary to this centrally driven hypophagia is poorly understood. Given the profound impact of SEMA on food intake and body weight, we propose that SEMA treatment reshapes gut microbial composition and that these shifts are correlated with metabolic outcomes. Diet-induced obese rats received a 4-week SEMA treatment and gut microbial composition was analyzed using 16S rRNA gene sequencing. To differentiate the impact of reduced food intake associated with SEMA from other effects of the drug treatment on the gut microbiome, a pair-fed to SEMA group was tested. SEMA significantly reduced body weight gain and food intake in both sexes. Significant SEMA-induced changes in microbial richness and evenness were detected. Linear discriminant analysis Effect Size (LEfSe) identified enrichment of Firmicutes taxa-particularly members of the Clostridiaceae family-in SEMA-treated rats, whereas controls showed greater representation of Bacteroidota taxa. Sex-specific associations between host metabolic parameters and gut microbial composition were also identified. These findings demonstrate profound, not necessarily health positive, partly sex-specific gut microbial community shifts following GLP-1 analogue treatment. Many of the changes in the gut microbiota were not simply driven by the decreased food intake. Thus, GLP-1 analogue treatment engages the gut microbiome through both food intake-dependent (brain-to-gut) and intake-independent pathways.
SN - 2040-4603
ER -